References
- Datta S, Grant DJW. Crystal structures of drugs: advances in determination, prediction and engineering. Nat Rev Drug Discov 2004;3:42–57
- Singhal D, Curatolo W. Drug polymorphism and dosage form design: a practical perspective. Adv Drug Deliv Rev 2004;56:335–47
- Moribe K, Tozuka Y, Yamamoto K. Supercritical carbon dioxide processing of active pharmaceutical ingredients for polymorphic control and for complex formation. Adv Drug Deliv Rev 2008;60:328–38
- Brittain HG. Polymorphism and solvatomorphism 2005. J Pharm Sci 2007;96:705–28
- Blagden N, de Matas M, Gavan PT, York P. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. Adv Drug Deliv Rev 2007;59:617–30
- Zweckberger K, Hackenberg K, Jung CS, et al. Glibenclamide reduces secondary brain damage after experimental traumatic brain injury. Neuroscience 2014;272:199–206
- Zhou Y, Fathali N, Lekic T, et al. Glibenclamide improves neurological function in neonatal hypoxia–ischemia in rats. Brain Res 2009;1270:131–9
- Blume H, Ali S, Siewert M. Pharmaceutical quality of glibenclamide products: a multinational postmarketing comparative study. Drug Dev Ind Pharm 1993;19:2713–41
- Hassan MA, Najib NM, Suleiman MS. Characterization of glibenclamide glassy state. Int J Pharm 1991;67:131–7
- Patterson JE, James MB, Forster AH, et al. The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. J Pharm Sci 2005;94:1998–2012
- Suleiman MS, Najib NM. Isolation and physicochemical characterization of solid forms of glibenclamide. Int J Pharm 1989;50:103–9
- Hassan MA, Sheikh Salem M, Sallam E, Al-Hindawi MK. Preparation and characterization of a new polymorphic form and a solvate of glibenclamide. Acta Pharm Hung 1997;67:81–8
- Panagopoulou-Kaplani A, Malamataris S. Preparation and characterization of a new insoluble polymorphic form of glibenclamide. Int J Pharm 2000;195:239–46
- Rehder S, Sakmann K, Rades T, Leopold CS. Thermal degradation of amorphous glibenclamide. Eur J Pharm Biopharm 2012;80:203–8
- Mitrevej A, Sinchaipanid N, Junyaprasert V, Warintornuwat L. Effect of grinding of β-cyclodextrin and glibenclamide on tablet properties. Part I: in vitro. Drug Dev Ind Pharm 1996;22:1237–41
- Chauhan B, Shimpi S, Paradkar A. Preparation and evaluation of glibenclamide–polyglycolized glycerides solid dispersions with silicon dioxide by spray drying technique. Eur J Pharm Sci 2005;26:219–30
- Iwata M, Ueda H. Dissolution properties of glibenclamide in combinations with polyvinylpyrrolidone. Drug Dev Ind Pharm 1996;22:1161–5
- Betageri GV, Makarla KR. Characterization of glyburide-polyethylene glycol solid dispersions. Drug Dev Ind Pharm 1996;22:731–4
- Tashtoush BM, Al-Qashi ZS, Najib NM. In vitro and in vivo evaluation of glibenclamide in solid dispersion systems. Drug Dev Ind Pharm 2004;30:601–7
- Shah SR, Parikh RH, Chavda JR, Sheth NR. Application of Plackett–Burman screening design for preparing glibenclamide nanoparticles for dissolution enhancement. Powder Technol 2013;235:405–11
- Yu L, Li C, Le Y, et al. Stabilized amorphous glibenclamide nanoparticles by high-gravity technique. Mater Chem Phys 2011;130:361–6
- Elkordy AA, Jatto A, Essa E. In situ controlled crystallization as a tool to improve the dissolution of glibenclamide. Int J Pharm 2012;428:118–20
- Salazar J, Müller RH, Möschwitzer JP. Application of the combinative particle size reduction technology H 42 to produce fast dissolving glibenclamide tablets. Eur J Pharm Sci 2013;49:565–77
- Leuner C, Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm 2000;50:47–60
- Pongpeerapat A, Wanawongthai C, Tozuka Y, et al. Formation mechanism of colloidal nanoparticles obtained from probucol/PVP/SDS ternary ground mixture. Int J Pharm 2008;352:309–16
- Byrn SR, McKenzie AT, Hassan MMA, Al-Badr AA. Conformation of glyburide in the solid state and in solution. J Pharm Sci 1986;75:596–600
- Steckel H, Rasenack N, Müller BW. In-situ-micronization of disodium cromoglycate for pulmonary delivery. Eur J Pharm Biopharm 2003;55:173–80